The present invention relates to stable liquid pharmaceutical compositions of Bortezomib or a pharmaceutically acceptable salt thereof. Further the present invention relates to liquid parenteral formulations of Bortezomib comprising of Bortezomib, one or more solvents and other pharmaceutically acceptable adjuvants thereof.